ProQR Therapeutics (PRQR) EBT (2012 - 2026)

ProQR Therapeutics has reported EBT for 14 years, with the latest figure at -$15.7 million in Q1 2026.

• Quarterly EBT fell 42.54% year-over-year to -$15.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$54.0 million (down 63.77% YoY) and the FY2025 annual result came in at -$50.4 million, down 68.58% from the prior year.
• EBT retreated to -$15.7 million in Q1 2026 per PRQR's latest filing, from -$11.7 million in the prior quarter.
• Over five years, EBT peaked at -$3.1 million in Q2 2024 and troughed at -$23.4 million in Q3 2022.
• A 5-year average of -$11.4 million and a median of -$11.0 million in 2025 frame the typical range for EBT.
• The sharpest annual moves came in 2023 and 2025: EBT soared 74.62% in 2023, then tumbled 342.01% in 2025.
• Over 5 years, EBT stood at -$13.6 million in 2022, then soared by 46.08% to -$7.3 million in 2023, then tumbled by 35.9% to -$9.9 million in 2024, then dropped by 17.34% to -$11.7 million in 2025, then plunged by 34.29% to -$15.7 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$15.7 million, -$11.7 million, and -$12.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.